Calmark strengthens sales and marketing team in preparation of global launch

Calmark Sweden AB has hired Maria Zavodnik for the role as Sales and Marketing Coordinator in order to strengthen its team for the global launch. Maria will take up position on March 24, 2021.

Maria Zavodnik has more than ten years’ experience in the medtech industry. Since 2019, her focus has been on IVD products, particularly related to coagulation. Maria is currently working as Sales Coordinator at Nordic Biomarker/Medirox AB and holds a M.Sc. in cellular and molecular biology from Uppsala University. Prior to joining Nordic Biomarker/Medirox, she gained a breadth of experience in sales, marketing and customer support at Bauerfeind Nordic AB.

“Calmark is an exciting company that develops important products in high demand for a large global market,” says Maria Zavodnik. “I am happy and full of anticipation to be part of the team that will take Calmark into the future!”

"I am very pleased that we have recruited this top performer to Calmark," says Anna Söderlund, CEO. “In view of the forthcoming global launch, we need to ensure our capacity at all stages; our products attract considerable international interest, and this reinforcement will make a great difference for our growth and development moving forward. I look forward to welcoming Maria to the team!”  

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.